UBA1 and VEXAS syndrome: Systemic corticosteroids are frequently administered empirically before the identification of the underlying UBA1 mutation and are considered a first-line treatment for managing the inflammatory symptoms and cytopenia associated with VEXAS syndrome [24,25].